ChromaDex Corp (CDXC)

2.65
0.07 2.60
NASDAQ : Health Care
Prev Close 2.72
Open 2.74
Day Low/High 2.57 / 2.74
52 Wk Low/High 2.46 / 6.18
Volume 65.79K
Avg Volume 151.40K
Exchange NASDAQ
Shares Outstanding 37.91M
Market Cap 99.70M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ChromaDex Reports 2016 Record Revenue As Ingredient Sales Grew 34%

ChromaDex Reports 2016 Record Revenue As Ingredient Sales Grew 34%

Q4 Total Revenue Increased 29% and 2016 Total Revenue Increased 22%

ChromaDex To Report Year End 2016 Financial Results On Thursday, March 16, 2017

ChromaDex To Report Year End 2016 Financial Results On Thursday, March 16, 2017

Company Will Host Investor Conference Call on Friday, March 17, 2017

Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent

Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent

Early findings demonstrated in female rats may one day lead to reductions in the neuropathic pain experienced by millions of breast and ovarian cancer patients and survivors

ChromaDex Expects To Report Record Fourth Quarter As Revenue Increased Approximately 29%

ChromaDex Expects To Report Record Fourth Quarter As Revenue Increased Approximately 29%

Q4 2016 Revenue is Expected to be Approximately $5.6 Million with Full-Year 2016 Revenue of Approximately $26.8 million

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

ChromaDex Opens New State-of-the-Art Research And Development Center In Longmont

R&D Facility an Important Milestone for ChromaDex to Continue Global Leadership in the Identification and Development of NAD+ Metabolites

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

Company's Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

Company Will Host Investor Conference Call on Thursday, November 10, 2016

Nicotinamide Riboside (NR) Plays A Critical Role In The Most Efficient Path To Cellular Energy Production

Nicotinamide Riboside (NR) Plays A Critical Role In The Most Efficient Path To Cellular Energy Production

Researchers' findings disprove the idea that there's a shortcut to NAD production

Published Studies In Humans And Mice Reveal How A Superior Vitamin B3 May Play An Important Role In Helping Us Enjoy Longer, Healthier Lives

Published Studies In Humans And Mice Reveal How A Superior Vitamin B3 May Play An Important Role In Helping Us Enjoy Longer, Healthier Lives

This vitamin, called NR, is exciting researchers as they discover more about its power to give us a more youthful metabolism

ChromaDex Adds New AnthOrigin™ To Its Proprietary Ingredient Portfolio

ChromaDex Adds New AnthOrigin™ To Its Proprietary Ingredient Portfolio

AnthOrigin™ naturally extracted anthocyanins are ideal for natural, clean label supplement innovation

Update: ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Update: ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Booth to feature a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise

ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Booth to feature, a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise

U.S. FDA Issues GRAS No Objection Letter For NIAGEN®

U.S. FDA Issues GRAS No Objection Letter For NIAGEN®

NR, a vitamin B3, affords food and beverage manufacturers a new opportunity to innovate

ChromaDex Reports Record Revenue As Ingredients Sales Climb 83% Compared To Previous Year Period

ChromaDex Reports Record Revenue As Ingredients Sales Climb 83% Compared To Previous Year Period

-Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000-

ChromaDex To Report Second Quarter 2016 Financial Results On Thursday, August 11, 2016

ChromaDex To Report Second Quarter 2016 Financial Results On Thursday, August 11, 2016

-Company Will Host Investor Conference Call on Thursday, August 11, 2016-

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.